HomeTrialNCT06902519
🔬NCT06902519Phase 1RECRUITING

Study of GS-0151 in Participants With Rheumatoid Arthritis

Study Summary

The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA). The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment75 participants
Primary Completion
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.113415+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.